^
Association details:
| Biomarker: | PML-RARA fusion |
|---|---|
| Cancer: | Acute Promyelocytic Leukemia |
| Drug: | cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) + idarubicin hydrochloride (Topoisomerase II inhibitor, DNA cross linking agent) + Altreno (tretinoin) (Retinoic acid receptor agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
[Microgranular-type acute promyelocytic leukemia with weak myeloperoxidase staining: difficulty of morphological diagnosis]
Excerpt:
...a 40-year-old woman with the microgranular variant of acute promyelocytic leukemia...PML-RARA mRNA detection finally led the patient to a definitive diagnosis. The patient achieved complete remission by induction chemotherapy including tretinoin, cytarabine and idarubicin, and no differentiation syndrome was observed.
DOI:
10.11406/rinketsu.61.1511
